Nautilus Biotech (Evry, France, www.nautilusbiotech.com) has signed a collaboration and license agreement with HanAll Pharmaceutical (Seoul, South Korea, www.hanall.co.kr) to develop and commercialize three Nautilus Biotech products in South Korea: Belerofon (Interferon alpha); Vitatropin (human growth hormone); and EporalTM (erythropoietin).
Nautilus Biotech (Evry, France, www.nautilusbiotech.com) has signed a collaboration and license agreement with HanAll Pharmaceutical (Seoul, South Korea, www.hanall.co.kr) to develop and commercialize three Nautilus Biotech products in South Korea: Belerofon (Interferon alpha); Vitatropin (human growth hormone); and EporalTM (erythropoietin).
The three Nautilus Biotech proprietary proteins included in the agreement have been designed for extended half-life and oral availability. By reducing the number and frequency of treatments needed and offering oral administration, these new drugs will enhance patient convenience and compliance.
Under the terms of the agreement, HanAll Pharmaceutical will develop, manufacture, and market the licensed products in the territory of South Korea. Nautilus Biotech will receive an upfront payment, milestone payments associated with development, and royalty payments based on net sales of products in South Korea.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.